| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LGALS1 |
| Uniprot No | P09382 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-135aa |
| 氨基酸序列 | ACGLVASNLN LKPGECLRVR GEVAPDAKSF VLNLGKDSNN LCLHFNPRFN AHGDANTIVC NSKDGGAWGT EQREAVFPFQ PGSVAEVCIT FDQANLTVKL PDGYEFKFPN RLNLEAINYM AADGDFKIKC VAFD |
| 预测分子量 | 14.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于LGALS1(Galectin-1)重组蛋白的代表性文献摘要概括：
1. **文献名称**：*Structural and functional studies of human galectin-1: a mediator of cell-cell adhesion*
**作者**：Levi G., Lädin B. et al.
**摘要**：该研究通过X射线晶体学解析了重组人Galectin-1的三维结构，揭示了其结合β-半乳糖苷配体的关键位点，并证明其在细胞间黏附及免疫调节中的生物学功能。
2. **文献名称**：*Galectin-1 suppresses autoimmune retinal disease by inhibiting effector T cells and promoting regulatory T cell activity*
**作者**：Toscano M.A., Bianco G.A. et al.
**摘要**：研究发现重组Galectin-1通过诱导活化的T细胞凋亡并增强调节性T细胞(Treg)的功能，显著缓解实验性自身免疫性视网膜病变，提示其在治疗自身免疫疾病中的潜力。
3. **文献名称**：*Recombinant human galectin-1 inhibits endothelial cell proliferation by modulating VEGF signaling*
**作者**：Thijssen V.L., Hulsmans S. et al.
**摘要**：文章表明重组Galectin-1通过干扰血管内皮生长因子(VEGF)受体信号通路，抑制血管内皮细胞增殖，为开发抗肿瘤血管生成疗法提供了理论基础。
(注：以上文献信息为模拟示例，实际引用时需核实具体文献来源及准确性。)
LGALS1. also known as galectin-1. is a member of the galectin family of β-galactoside-binding proteins. It is a 14.5 kDa protein encoded by the LGALS1 gene and functions as a homodimer through non-covalent interactions. Galectin-1 plays multifaceted roles in cellular processes, including immune regulation, cell adhesion, apoptosis, and angiogenesis. It binds to glycoproteins containing poly-N-acetyllactosamine chains via its conserved carbohydrate recognition domain (CRD), mediating interactions between cells and the extracellular matrix.
In physiological contexts, LGALS1 is expressed in various tissues, such as immune cells (T cells, macrophages), endothelial cells, and neurons. It exhibits immunomodulatory properties by promoting T-cell apoptosis, dampening pro-inflammatory responses, and facilitating immune tolerance. However, its dysregulation is linked to pathological conditions, including cancer progression, chronic inflammation, and fibrosis. Tumor cells often overexpress LGALS1 to evade immune surveillance or enhance metastasis, making it a potential therapeutic target.
Recombinant LGALS1 protein is produced using expression systems like E. coli or mammalian cells, ensuring high purity and bioactivity for research applications. Its production enables mechanistic studies on ligand interactions, signaling pathways, and structure-function relationships. Researchers utilize it to explore roles in autoimmune diseases, neural repair, and cancer immunotherapy. For example, recombinant LGALS1 has been tested in preclinical models to suppress graft-versus-host disease or modulate macrophage polarization. Despite its therapeutic potential, challenges remain in balancing its context-dependent pro- and anti-tumor effects. Ongoing studies aim to optimize its clinical translation through engineered variants or targeted delivery strategies.
×
